Immunic | VTL - Operating Profit


Immunic reported $-25.73M in Operating Profit for its fiscal quarter ending in September of 2024.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Grifols EUR 320.55M 91.01M Dec/2025
Immunic USD -25.73M 2.91M Sep/2024
Insmed USD -249.71M 11.64M Dec/2025
Omeros USD -35.41M 23.75M Sep/2024
OraSure Technologies USD -13.59M 2.13M Dec/2025
Quidel USD -37.3M 667.5M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025
Xoma USD -15.64M 5.56M Sep/2024